Fig 1.
Decision tree of the exploratory initial two-month phase prior to the Markov model.
a. Source: Expert panel Faber et al. (2008)[2] b. Source: Expert panel Faber et al. (2008)[2] c. Source: Gau et al. (2008)[17]
Fig 2.
Markov model IR-MPH treatment with daily transition probabilities and utilities on an annual basis (QALY).
QALY = Quality adjusted life years a Source: Lloyd et al. (2011) [19] b Source: Wong et al. (2009) [18] c Source: Expert panel Faber et al. (2008) [2] d Source: Faber et al. (2008) [2] e Source: Biederman et al. (2000) [20] f Source: Remaining probabilities
Fig 3.
Markov model ER-MPH treatment with daily transition probabilities and utilities on an annual basis (QALY).
QALY = Quality adjusted life years a Source: Lloyd et al. (2011) [19] b Source: Wong et al. (2009) [18] c Source: Expert panel Faber et al. (2008) [2] d Source: Faber et al. (2008) [2] e Source: Steele et al. (2006) [21] f Source: Biederman et al. (2000) [20] g Source: Remaining probabilities
Table 1.
Markov model results of base case analysis per switcher per 10 years.
Fig 4.
Effect of the univariate sensitivity analyses on the outcome of costs (€) (IR-MPH vs ER-MPH). Illustrative result for ER-MPH, example of MPH-OROS.
tp = transition probability, SR = suboptimal response, OR = optimal response, DT = discontinuing treatment, NR = natural remission, IR-MPH = immediate release methylphenidate, ER-MPH = extended release methylphenidate.
Fig 5.
Effect of the scenario analyses on the outcome of costs (€) (IR-MPH vs ER-MPH). Illustrative result for ER-MPH, example of MPH-OROS.
tp = transition probability, SR = suboptimal response, OR = optimal response, DT = discontinuing treatment, NR = natural remission, IR-MPH = immediate release methylphenidate, ER-MPH = extended release methylphenidate.
Fig 6.
Effect of the univariate sensitivity analyses on the outcome of effect (QALY) (IR-MPH vs ER-MPH). Illustrative result for ER-MPH, example of MPH-OROS.
tp = transition probability, SR = suboptimal response, OR = optimal response, DT = discontinuing treatment, NR = natural remission, IR-MPH = immediate release methylphenidate, ER-MPH = extended release methylphenidate.
Fig 7.
Effect of the scenario analyses on the outcome of effect (QALY) (IR-MPH vs ER-MPH). Illustrative result for ER-MPH, example of MPH-OROS.
tp = transition probability, SR = suboptimal response, OR = optimal response, DT = discontinuing treatment, NR = natural remission, IR-MPH = immediate release methylphenidate, ER-MPH = extended release methylphenidate.
Fig 8.
Cost and effect differences of probabilistic sensitivity analysis in cost-effectiveness plane and 95% confidence interval (Illustrative result for ER-MPH, example of MPH-OROS).
QALY = Quality adjusted life years